NCT02070289View on ClinicalTrials.gov

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy

Interventions

DRUG

PF-06372865

Tablets, 2.5 mg BID, 14 days

DRUG

Placebo

Tablets, BID, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

DRUG

Placebo

Tablets, BID or titration, 14 days

DRUG

PF-06372865

Tablets, to be decided dose, BID or titration, 14 days

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT02070289 - A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2) | Biotech Hunter | Biotech Hunter